![](\"https:\/\/mms.businesswire.com\/media\/20260722951066\/en\/2857395\/5\/softgels.jpg\")
<\/a><\/a>![](\"https:\/\/mms.businesswire.com\/media\/20260722951066\/en\/1823118\/5\/Timeline_powered_by_Mitopure.jpg\")
<\/a><\/a>\nThe order, entered July 15, 2026 by Judge Myong J. Joun in Amazentis SA et al. v. The Partnerships and Unincorporated Associations Identified on Schedule \u201cA\u201d, Case No. 1:25-cv-12913-MJJ (District of Massachusetts), permanently enjoins 19 defaulting defendants from further manufacturing, marketing, distributing, or selling Urolithin A products (see full list in Notes to Editors below).<\/p>
\nTimeline and Timeline Longevity, Inc. filed suit in October 2025, alleging that 30 defendants, operating through a network of online storefronts and private drop-ship stores, sold products marketed as containing Urolithin A that either contained no detectable Urolithin A whatsoever or contained Urolithin A at levels materially below the amount represented on the product label. In certain instances, defendants also used Timeline\u2019s Mitopure\u00ae trademark without authorization to promote these falsely labeled products.<\/p>
\nIndependent laboratory testing commissioned by Timeline confirmed that products sold under these brands, many purchased by consumers seeking clinically validated cellular health benefits, contained no detectable Urolithin A or only a fraction of what was advertised. Additional evidence further demonstrated that defendants made a range of additional false and misleading claims, including that their products were made in the USA, were third-party tested and certified, and were vegan. Timeline also showed that many defendants provided false address information on product packaging and listings; and that they included undisclosed filler ingredients in their mislabeled Urolithin A products. Timeline previously entered stipulated judgments with those defendants that did appear in the case.<\/p>
\nFor the remaining 19 defendants that failed to appear or otherwise respond to the complaint, the Court entered default judgment in Timeline\u2019s favor.<\/p>
\n\u201cWe are very pleased with the Court's order that protects consumers and innovators like Timeline from bad actors who sell fraudulent products and misappropriate intellectual property,\" said Chris Rinsch, PhD, Co-Founder and President of Timeline. \"Timeline has invested over 18 years and more than $50 million USD building the clinical evidence for our proprietary Mitopure\u00ae Urolithin A. Timeline will continue to vigilantly protect the integrity of the market. We will not hesitate to pursue available legal remedies against those who put consumers at risk and exploit our intellectual property without authorization.\"<\/i><\/p>
\nThe permanent injunction bars the 19 defendants and those acting in concert with them from continuing to import, market, advertise, distribute, offer for sale, or sell any product represented as containing Urolithin A. In addition, the Court has ordered the 19 defendants to pay damages to Timeline ranging from $500 to more than $2.7 million per defendant, reflecting the scope of each defendant's sale of fraudulent products. For a number of the defendants, the Court tripled the award as \u201cenhanced damages.\u201d The total damages awarded to Timeline on account of the 19 defendants\u2019 sale of fraudulent products is more than $5.3 million.<\/p>
\nThis case is part of Timeline\u2019s ongoing global enforcement program to protect consumers from counterfeit and mislabeled Urolithin A products, to safeguard the integrity of the Urolithin A market, and to defend the clinical research and intellectual property that form the foundation of that market and Timeline\u2019s work.<\/p>